Mobile

A trial to assess the safety, tolerability and immunogenicity of Repevax® and rLP2086 vaccine when given together in healthy subjects aged ≥11 to <19 years

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-022449-38

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that the immune response induced by Repevax given with the bivalent rLP2086 vaccine (group 1) is non-inferior to the immune response induced by Repevax alone (group 2) when measured 1 month after vaccination 1. The immune responses to all components of Repevax will be assessed.

Critère d'inclusion

  • Healthy volunteers (prevention of bacterial meningitis)

Liens